We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+42.48%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$228M
AUM Growth
+$9.22M
Cap. Flow
-$20.8M
Cap. Flow %
-9.11%
Top 10 Hldgs %
62.39%
Holding
90
New
18
Increased
18
Reduced
19
Closed
27

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$13.7M
2
MRK icon
Merck
MRK
+$9.87M
3
DHR icon
Danaher
DHR
+$3.66M
4
SNY icon
Sanofi
SNY
+$2.9M
5
MDT icon
Medtronic
MDT
+$2.48M

Top Sells

Rank Stock Value
1
QCP
Quality Care Properties, Inc.
QCP
+$23.1M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.94M
3
AERI
Aerie Pharmaceuticals
AERI
+$6.83M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.25M
5
NVRO
NEVRO CORP.
NVRO
+$3.78M

Sector Composition

Rank Sector Weight
1 Healthcare 78.99%
2 Miscellaneous 12.59%
3 Industrials 7.51%
4 Communication Services 0.5%
5 Real Estate 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDCO
51
DELISTED
Medicines Co
MDCO
$500K 0.22%
16,717
-22,600
-57% -$851K
IOVA icon
52
Iovance Biotherapeutics
IOVA
$3.63B
$497K 0.22%
44,140
-10,860
-20% -$154K
SPNE
53
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$481K 0.21%
30,899
– –
DERM
54
DELISTED
Dermira, Inc.
DERM
$436K 0.19%
40,018
+20,000
+100% +$202K
VKTX icon
55
Viking Therapeutics
VKTX
$3.75B
$436K 0.19%
+25,000
New +$298K
TGTX icon
56
TG Therapeutics
TGTX
$8.26B
$364K 0.16%
65,000
-15,000
-19% -$171K
ISEE
57
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$352K 0.15%
149,100
– –
DVAX
58
DELISTED
Dynavax Technologies
DVAX
$335K 0.15%
27,000
– –
FOMX
59
PUT
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$143K 0.06%
+25,000
New +$143K
CFMS
60
DELISTED
Conformis, Inc. Common Stock
CFMS
$134K 0.06%
5,074
– –
AGTC
61
DELISTED
Applied Genetic Technologies Corporation
AGTC
$106K 0.05%
+14,500
New +$63.5K
MLNT
62
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$105K 0.05%
5,296
-10,071
-66% -$255K
IMUX icon
63
PUT
Immunic
IMUX
$210M
$10.5K ﹤0.01%
+96
New +$251K
ABUS icon
64
Arbutus Biopharma
ABUS
$1B
– –
-97,495
Closed -$712K
ALNY icon
65
Alnylam Pharmaceuticals
ALNY
$31.7B
– –
-63,493
Closed -$6.25M
BMRN icon
66
BioMarin Pharmaceuticals
BMRN
$12.5B
– –
-84,257
Closed -$7.94M
CLLS
67
Cellectis
CLLS
$342M
– –
-30,000
Closed -$849K
EHTH icon
68
eHealth
EHTH
$38.4M
– –
-56,546
Closed -$1.25M
GLMD icon
69
Galmed Pharmaceuticals
GLMD
$4.34M
– –
-7
Closed -$119K
HAE icon
70
Haemonetics
HAE
$4.73B
– –
-14,646
Closed -$1.31M
IRMD icon
71
iRadimed
IRMD
$1.11B
– –
-17,608
Closed -$365K
TNDM icon
72
Tandem Diabetes Care
TNDM
$1.49B
– –
-61,300
Closed -$1.35M
VCEL icon
73
Vericel Corp
VCEL
$2.1B
– –
-74,837
Closed -$726K
NVRO
74
DELISTED
NEVRO CORP.
NVRO
– –
-47,279
Closed -$3.78M
CDMO
75
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
– –
-100,402
Closed -$394K
1 2
3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q3 2018 Portfolio in Review

As of Q3 2018, Eversept Partners held 90 positions worth $228M, up 4.2% from $219M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Eversept Partners withdrew a net $20.8M in Q3 2018, closing 27 positions and reducing 19 holdings. Its most notable exit was Quality Care Properties, Inc., an estimated $23.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 73% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, Eversept Partners opened a new position in Merck worth $10.6M.

  • Eversept Partners's largest Q3 2018 buy was Merck: 154,894 shares worth $10.6M.
  • Eversept Partners added most to Zogenix, Inc. in Q3 2018, an estimated $13.7M increase.
  • Eversept Partners's biggest Q3 2018 reduction was Aerie Pharmaceuticals, cutting an estimated $6.83M.
  • Eversept Partners fully exited Quality Care Properties, Inc. in Q3 2018, selling an estimated $23.1M.
  • Eversept Partners's ten largest holdings make up 62% of its $228M portfolio in Q3 2018.
  • Eversept Partners opened 18 new positions and closed 27 in Q3 2018.
  • Eversept Partners's portfolio value rose 4.2% quarter-over-quarter to $228M.

Based on Eversept Partners's 13F filing for Q3 2018, filed 14 Nov 2018.